Inherent flaws and infrastructural limitations of the global healthcare systems result in substantial inefficiency, wastage and sub-optimal health outcomes for the most important stakeholder; the patient.
Innovative pricing models provide viable solutions to the aforementioned problems. Unfortunately, most healthcare providers or payers around the world lack the relevant infrastructure to track and implement outcomes-based pricing agreements, and so are shy in adopting innovative pricing contracts and policies. In healthcare today, there is a lack of incentive for health systems and providers to focus on mutually beneficial collaboration and the maximization of patient outcomes. Though it is widely agreed that the transition to value-based pricing is necessary, progress in doing so has been slow.
Digipharms’ solutions aim to accelerate the much needed restructuring of healthcare delivery systems to a value-based approach. The inherent flaws of current global healthcare infrastructure result in substantial inefficiency, wastage and sub-optimal health outcomes for the most important stakeholder; the patient. In healthcare today, there is a lack of incentive for health systems and providers to focus on mutually beneficial collaboration and the maximisation of patient outcomes.
Value-Based Care
Healthcare systems around the world are currently threatened by challenges unique to our time; unsustainable expenditure, aging populations and the increasing prevalence of chronic diseases. The concept of value-based healthcare proposes that pay for healthcare should be tied to the quality of care and the benefits it provides; switching from a ‘fee for service’ to a ‘fee for performance’ reimbursement model.
Innovative Pricing
Innovative pricing solutions such as value-based pricing offer an increasingly dynamic solution to address the uncertainty around the cost of treatment relative to patient outcomes. Such mechanisms reward manufacturers and providers for improving patient outcomes, incentivize innovation and encourage the transition to patient-centric healthcare.
Pioneering Evidence Generation
Innovative evidence generation solutions are necessary to satisfy the requirement of relevant, timely and quality data to inform the provision of optimized value-based healthcare. Circumventing the use of static or retrospective data will open the horizon to superior forecasting, confidence in decision making and global oversight with regards to current developments in an increasingly dynamic industry such as healthcare.
DPH Token
DPH Supply: 100,000,000 Fixed (ERC-20)
Ticker code: DPH
Decimal Places: 18
Token Price 1.00 USD
Token Sale
Pre - Sale: 15,000,000 DPH
Base Price: $1.00 USD
Pre - Sale Discount: 35%
Pre - Sale Length: 4 Weeks
Main Sale: 50,000,000 DPH
Week 1: 25% (Capped at 25 million tokens)
Week 2: 15% (Capped at 15 million tokens)
Week 3: 10% (Capped at 10 million tokens)
Week 4: 1.00 USD
Team
- Ahmed Abdulla - Founder/CEO
- Girisha Fernando - Co-Founder/COO
- Zach Daniels - CTO
- Ralf Gerteis - Commercial Strategy
- Alexander Sverdlov - Cybersecurity Strategy
- Meredith Darden - Digital Marketing Lead
- Alexey Popov - Web Development
- Michael Gubert - UI/UX Design
- Leon Rebolledo - Lead Architect
- Rolf Günter - Legal Counsel
- Bobby Kaura - Business Development
- Dr. Mohamed Abdulla - Clinical Transformation
- Dr. Hasham Al-Meshhedani - Patient Engagement
- Ali Al-Sudani - Clinical Pharmacist
- Dr. Rami Radwan - Clinical Relations
- Peter Sandbach - Communications Director
- Debra De Silva-Sun - HEOR & Pricing Analyst
- Marko Granic - Graphic Designer
For More Information :
Website: https://www.digipharm.ch/
Whitepaper: https://digipharm.ch/docs/DigipharmWP.pdf
Facebook: https://www.facebook.com/digipharmteam/
Twitter: https://twitter.com/DigipharmTeam
Telegram: https://t.me/digipharm
Profile Bitcointalk: https://bitcointalk.org/index.php?action=profile;u=1113772
ETH : 0xd395c300C4999FB0846D9Ba9Fe4002cD0839837d